Navigation Links
MedImmune Resolves FDA Observations Regarding Manufacturing Process for FluMist(R)
Date:9/7/2007

FluMist Expected to Be Available Soon for 2007-2008 Season

GAITHERSBURG, Md., Sept. 7 /PRNewswire/ -- MedImmune announced today that it has resolved the observations made by the U.S. Food and Drug Administration (FDA) during an annual inspection of the company's influenza vaccine manufacturing facility in Speke, United Kingdom. The agency's observations led to the issuance of a Warning Letter on May 24, 2007, which has now been resolved. The UK facility is the bulk manufacturing site for FluMist(R) (Influenza Virus Vaccine Live, Intranasal). MedImmune will continue to work with the FDA on the implementation and ongoing execution of all quality and compliance commitments.

MedImmune is currently working with the FDA on the standard annual lot release process so that shipping of FluMist to customers can soon begin for the upcoming influenza season. MedImmune can now also take the necessary regulatory steps to seek the FDA's final approval of the company's supplemental biologics licensing application requesting expansion of the vaccine's indication to include children below 5 years of age.

About FluMist

FluMist is currently indicated for active immunization for the prevention of disease caused by influenza A and B viruses in healthy children and adolescents, 5 to 17 years of age, and healthy adults, 18 to 49 years of age. There are risks associated with all vaccines, including FluMist. As with any vaccine, FluMist does not protect 100 percent of individuals vaccinated and may not protect against viral strains not contained in the vaccine.

Under no circumstances should FluMist be administered as an injection (i.e. parenterally). FluMist is contraindicated in persons with hypersensitivity to any component of the vaccine, including eggs; in children and adolescents receiving aspirin therapy or aspirin-containing therapy; in individuals with a history of Guillain-Barre syndrome; and in individuals with known or suspected immune def
'/>"/>

SOURCE MedImmune
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Kenya Resolves to Fight Tuberculosis
2. IIT Delhi Scientist Finds Climate Models Consistent With Ocean Warming Observations
3. Fresh warnings to doctors regarding abortion pill
4. Researchers Present Data Regarding The Efficiency Of Herbs
5. Will anxiety regarding fertility treatment affect the chances of conception?
6. Changing Trends Regarding Insurance Cover For Weight Reduction Surgery
7. Indian Government warns Gujarat regarding possibility of bird flu
8. Leeches Provide Clues Regarding The Prevention Of Heart Disease
9. AIDS control requires co-coordinated move regarding safe sexual practices
10. Legal Action against Authority Regarding Outbreak of Legionnaires’ Diseas
11. Mixed Opinion Regarding Common Medical And Engineering Entrance Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... shown that some high-profile athletes who suffered repeated blows ... clumps in their brains. Those clumps suggest the athletes ... scientists are working on tests that might be able ... an article in Chemical & Engineering News (C&EN) ... Society. , In the article, Lauren Wolf, a senior ...
(Date:7/23/2014)... together for the first time to call for better ... worldwide suffering from the condition. , Psoriatic arthritis (PsA) ... damage if left untreated. , PsA tends to affect ... red, scaly rash, and affects approximately two per cent ... in five go on to develop PsA usually ...
(Date:7/23/2014)... Louis (PRWEB) July 23, 2014 Five years ... its doors there were few options for babies diagnosed with ... delivery, or travel across the country for innovative fetal therapies. ... Fetal Care Institute to care for their babies in the ... surgeries and interventions. , “A number of the babies ...
(Date:7/23/2014)... models of human oral cancer treated with an agent ... surrounding tissues, researchers from the School of Dentistry and ... Science Center at San Antonio found. The Health Science ... study, which is described in the journal Oral ... , Oral squamous cell carcinoma is the eighth most ...
(Date:7/23/2014)... July 23, 2014 SpaRoom® ... SpaRoom’s top product and premier diffuser, is now available ... and an improved motor for maximum quality. The new ... now available on SpaRoom.com for $60 along with the ... ultrasonic pulsations to create a long-lasting, tranquil mist. Add ...
Breaking Medicine News(10 mins):Health News:Psoriatic arthritis patients need better screening, warns panel of experts 2Health News:St. Louis Fetal Care Institute Marks Five Years of Life Changing Care and Fetal Surgery 2Health News:Anti-pain agent shrinks oral cancers, leaves healthy tissues alone 2Health News:SpaRoom® Unveils New Sleek Color, Improved AromaMist™ 2
... to The Diabetes Research Institute of Miami on ... behalf of the motorcycle franchisee, ... check to The Diabetes Research Institute of Miami in honor ... the,leading voluntary insurer announced the motorcycle franchisee as its,100,000th Online ...
... epilepsy and depression, researchers say , , FRIDAY, ... deep brain stimulation sensor that can monitor levels ... Clinic researchers and colleagues. , The wireless instantaneous ... the brain to provide real-time measurement of chemicals ...
... Local Patients May Be at,Risk, PHILADELPHIA, Sept. 12 ... blood supply alert for New Jersey and,southeastern Pennsylvania., ... critical need for Type O,blood. Brigid O,Neill-LaGier, Chief Executive ... the community to donate blood. "The blood,supply is a ...
... reports a hiring trend over the past four months within High-Tech ... is has become a “recruiters” market causing both parties to change ... ... 2008 -- Lucas Group, an executive search firm, today reports a ...
... yearn to wear the sheer, body-hugging fashions available today, we ... dreaded back fat rolls and lumps. A study published in ... the official medical journal of the American Society of Plastic ... these unsightly bumps and bulges while hiding the scar under ...
... ATSI ), manufacturer and marketer of state-of-the-art ... unprecedented number,of scientific presentations and symposia will focus ... for Cardio-Thoracic Surgeons (EACTS),meeting. The EACTS is a ... and is being held in Lisbon, Portugal from ...
Cached Medicine News:Health News:Aflac Celebrates With Peterson's Harley Davidson of Miami as 100,000th Online Billing Customer 2Health News:American Red Cross Issues Local Blood Supply Alert 2Health News:American Red Cross Issues Local Blood Supply Alert 3Health News:Lucas Group Reports Hiring Trend in High-Tech Medical Device 2Health News:Say 'goodbye' to back fat rolls 2Health News:ATS Medical Products Featured Prominently in Scientific Presentations at European Association for Cardio-Thoracic Surgeons (EACTS) Annual Meeting 2Health News:ATS Medical Products Featured Prominently in Scientific Presentations at European Association for Cardio-Thoracic Surgeons (EACTS) Annual Meeting 3Health News:ATS Medical Products Featured Prominently in Scientific Presentations at European Association for Cardio-Thoracic Surgeons (EACTS) Annual Meeting 4
(Date:7/23/2014)... 2014 Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) ... and research facility: Ampio Pharmaceuticals, 373 Inverness ... (720) 437-6500 Michael Macaluso , Ampio,s ... facility will be fully operational this summer, right ... Ampion TM necessary to accommodate the company,s BLA ...
(Date:7/23/2014)... 23, 2014  ArmaGen, a privately held biotechnology ... severe neurological disorders, announced today that it has ... with Shire plc to develop AGT-182, an investigational ... both the central nervous system (CNS) and somatic ... MPS II, Hunter syndrome is a rare, severe, ...
(Date:7/22/2014)... TOKYO , July 23, 2014   ... Taiho Pharmaceutical Co., Ltd. (hereinafter "Taiho"), a ... the company will be investing US$30 million in Remiges ... venture capital fund. Taiho has a long ... needs of oncologists and cancer patients. Our development of ...
Breaking Medicine Technology:Ampio Pharmaceuticals announces the opening of its new headquarters, manufacturing and research facility in Englewood Colorado 2ArmaGen Announces Strategic Licensing and Collaboration Agreement with Shire to Develop AGT-182 for Treatment of Hunter Syndrome 2ArmaGen Announces Strategic Licensing and Collaboration Agreement with Shire to Develop AGT-182 for Treatment of Hunter Syndrome 3Taiho Pharmaceutical Invests US$30 Million in Remiges BioPharma Fund, LP 2
... Abbott (NYSE: ABT ) scientists and independent researchers ... Abbott,s investigational oncology compounds at this year,s American Society ... June 4-8 in Chicago . The presentations include ... and a humanized monoclonal antibody directed against CS1. Abbott,s oncology ...
... EAST HANOVER, N.J. , June 3 ... study of Afinitor® (everolimus) tablets plus best supportive care met ... or time without tumor growth, in patients with advanced pancreatic ... I n A dvanced N euroendocrine T ...
Cached Medicine Technology:Abbott to Present Data on Several Investigational Cancer Treatments at American Society of Clinical Oncology Annual Meeting 2Abbott to Present Data on Several Investigational Cancer Treatments at American Society of Clinical Oncology Annual Meeting 3Abbott to Present Data on Several Investigational Cancer Treatments at American Society of Clinical Oncology Annual Meeting 4Abbott to Present Data on Several Investigational Cancer Treatments at American Society of Clinical Oncology Annual Meeting 5Abbott to Present Data on Several Investigational Cancer Treatments at American Society of Clinical Oncology Annual Meeting 6Abbott to Present Data on Several Investigational Cancer Treatments at American Society of Clinical Oncology Annual Meeting 7Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors 2Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors 3Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors 4Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors 5Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors 6Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors 7
... Forma 1400 Series ... specifically to revolutionize working ... cabinet. The most comfortable, ... Class II cabinet on ...
... The Premier 12 Holter Analysis Kit incorporates ... Dispersion with other powerful DMS Holter analysis ... TWA analysis possible in less than 10 ... TWA, for visual verification and validation. The ...
... Designed for ease of use and patient ... smooth edges for comfort and is available ... to a perfect fit. For hard to ... trach collar to your specifications. Don't just ...
... more comfortable, and you will too., ... and to avoid the knotty problems associated ... ties, consider the Dale® Tracheostomy Tube Holder. ... narrow fastener tabs of the Dale® Tracheostomy ...
Medicine Products: